Recent Finacing
Recent Raise
Neuron23 is a clinical-stage biotechnology company developing precision medicines for Parkinson’s disease, targeting LRRK2-driven forms of the disorder.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Neuron23.
